Merck/Schering’s Vytorin Clears FDA: Price Is 22% Discount To Lipitor
Executive Summary
Merck/Schering-Plough's cholesterol-lowering agent Vytorin will carry a wholesale acquisition cost that is a 22% discount to the three highest doses of Pfizer's Lipitor
You may also be interested in...
Merck Sales Force More Focused, Not Smaller, After Vioxx Withdrawal
Merck sales reps will detail fewer products to fewer doctors under a reorganized structure, the company told analysts during its investor day Dec. 14
Merck Sales Force More Focused, Not Smaller, After Vioxx Withdrawal
Merck sales reps will detail fewer products to fewer doctors under a reorganized structure, the company told analysts during its investor day Dec. 14
Sen. Baucus Urges More Comparative Research At Vioxx Hearing
The Vioxx withdrawal demonstrates the need for more comparative research on drugs, Sen. Max Baucus (D-N.M.) suggested in his questioning of witnesses at the Senate Finance Committee's hearing on Merck's withdrawal of the COX-2 inhibitor